Benchling Collaborates with Lilly TuneLab to Enhance AI Access
Today, Benchling announced an exciting collaboration with Lilly TuneLab, an innovative platform for artificial intelligence and machine learning designed by Eli Lilly. This partnership aims to democratize access to powerful AI tools that are based on extensive research data amounting to over $1 billion. The integration will enable scientists to seamlessly incorporate Lilly's TuneLab prediction models into their existing processes within Benchling's platform.
The Vision Behind the Partnership
According to Sajith Wickramasekara, CEO and co-founder of Benchling, this collaboration is a priority for reaching scientists worldwide. He states, "Lilly chose Benchling as a priority platform partner for TuneLab distribution and data orchestration because we're where scientists already work." This reflects their commitment to making AI technology more accessible in the scientific community.
Enhancing R&D Efficiency
As the field of biotechnology rapidly evolves, the integration of AI into research and development continues to gain traction. Recent studies show that 81% of early adopters are already utilizing AI models in their R&D processes. However, many organizations face challenges with the quality of their data and lack the necessary infrastructure to implement AI solutions effectively. Benchling's partnership with Lilly TuneLab addresses these critical issues by providing access to robust models trained on high-quality data.
Unlocking New Potential
The partnership will significantly benefit scientists looking to leverage AI in various stages of drug development. Lilly's TuneLab was launched with the goal of optimizing drug safety and efficacy through advanced models powered by extensive datasets from numerous unique molecules. This collaboration further strengthens Benchling's position as a leading platform for scientific research, positioning it at the forefront of biotech innovation.
Bridging Gaps in Data Accessibility
One major hurdle in the biotech industry is the scarcity of high-quality datasets and secure frameworks necessary for successful AI implementation. Benchling's 2026 Biotech AI Report emphasizes that these challenges are the top reasons AI initiatives often fall short. By partnering with Lilly TuneLab, Benchling aims to provide a solution that empowers companies of all sizes to access advanced AI models that can drive innovation and improve research outcomes.
Upcoming Features for Benchling Users
Later this year, users of the Benchling platform will have the opportunity to opt into utilizing Lilly's proprietary models, enabling them to incorporate AI into their scientific workflows. With this integration, Benchling continues to evolve as a valuable resource for researchers, allowing them to enhance their work through the use of AI technology.
About Benchling
With a mission to unlock the power of biotechnology, Benchling was founded in 2012 and has since become a trusted platform for over 1,300 biotech companies globally. Their cloud-based system serves both innovative startups and established giants in the biopharma sector. Benchling's product suite enables scientists to capture, connect, and analyze valuable data across the R&D lifecycle, streamlining their efforts and leading to groundbreaking discoveries.
Frequently Asked Questions
What is the purpose of the partnership between Benchling and Lilly TuneLab?
The partnership aims to make advanced AI-powered models accessible to researchers, enhancing their ability to streamline workflows and improve research outcomes.
What type of data will scientists have access to through the TuneLab integration?
Scientists will gain access to data from Lilly's extensive research, focused on drug safety and efficacy, powered by AI models designed to interpret this data effectively.
What challenges does this partnership address in the biotech industry?
The partnership addresses challenges like data quality, accessibility, and the need for secure infrastructure to effectively leverage AI in research and development.
How will Benchling's customers benefit from this collaboration?
Customers can integrate Lilly's AI models directly into their workflows, increasing efficiency and enabling them to utilize advanced predictions for antibody and molecule development.
What is Benchling's overall mission?
Benchling's mission is to unlock the potential of biotechnology by providing a unified platform that enhances the R&D lifecycle for scientists, making their work more impactful.
